Among the most resistant forms of breast cancer, triple-negative tumors carrying TP53 mutations have long confounded oncologists — particularly when the LIG1 gene is lost, rendering platinum chemotherapy ineffective. Researchers at Baylor College of Medicine have now turned that genetic vulnerability on itself, discovering that combining two DNA repair inhibitors, olaparib and ceralasertib, can trap these cells in a state they cannot survive. The work, grounded in mechanistic precision rather than trial and error, offers a rational path forward for patients who have exhausted conventional opti
Researchers identify drug combo to overcome chemotherapy resistance in aggressive breast cancer
Triple-negative breast cancer patients with TP53 mutations and LIG1 loss currently face chemotherapy resistance, limiting treatment options for this aggressive cancer subtype.
A marker of treatment failure becomes a signal for a specific strategy
Mark
So these patients already have a cancer that's hard to treat. And then they find out their tumors are resistant to the drugs that are supposed to work. That sounds like a dead end.
Mimi
It was, until the researchers realized that the thing making them resistant—the LIG1 loss—was also a weakness. The cancer cells became dependent on other repair pathways to survive. Once you know that, you can target those pathways.
Mark
But why does combining two drugs work better than one? Isn't that just more toxicity?
Mimi
Not necessarily. It's about precision. Each drug blocks a different repair pathway. Together, they leave the cancer cell nowhere to go. It's like closing all the exits at once.
Mark
And the biomarker—LIG1 status—that's the real innovation here, isn't it? Not just the drug combination, but knowing who needs it.
Mimi
Exactly. Right now, oncologists treat triple-negative breast cancer somewhat blindly. With LIG1 testing, they could say: this patient's tumor has low LIG1, so this combination is worth trying. It's personalization based on mechanism, not guesswork.
Mark
How far away is this from actual patients?
Mimi
It's in animal models now. The next step is clinical trials. If those work, you're looking at maybe a few years before it could be available. But the foundation is solid—the science is mechanistic, the drugs already exist, and the biomarker is measurable.
The Pulse
- Triple-negative breast cancer with TP53 mutations is one of oncology's most resistant subtypes, and the loss of the LIG1 gene has historically meant chemotherapy simply stops working.
- For years, LIG1 loss was only bad news — a signal of treatment failure with no actionable response available to clinicians.
- Baylor researchers flipped the question: if LIG1 loss creates resistance, could it also expose a weakness — and a systematic screen of 120 drug combinations pointed to a striking answer.
- Combining olaparib and ceralasertib blocked two critical DNA repair pathways simultaneously, trapping tumor cells with nowhere to turn in preclinical cell and animal models.
- LIG1 status can now be measured before treatment begins, transforming a marker of failure into a guide for selecting patients most likely to benefit from this combination.
- Clinical trials are the next frontier, where the precision of the laboratory must prove itself in the lives of patients who have run out of other options.
Among the most resistant forms of breast cancer, triple-negative tumors carrying TP53 mutations have long confounded oncologists — particularly when the LIG1 gene is lost, rendering platinum chemotherapy ineffective. Researchers at Baylor College of Medicine have now turned that genetic vulnerability on itself, discovering that combining two DNA repair inhibitors, olaparib and ceralasertib, can trap these cells in a state they cannot survive. The work, grounded in mechanistic precision rather than trial and error, offers a rational path forward for patients who have exhausted conventional options — and a biomarker, LIG1 status, that may finally allow medicine to find them before it is too late.
Triple-negative breast cancer is one of oncology's harshest diagnoses — fast-moving, hormone-receptor-free, and resistant to the targeted therapies that have transformed outcomes elsewhere. When tumors also carry TP53 mutations, the picture darkens further: many of these patients develop resistance to platinum-based chemotherapy, the standard treatment. Researchers at Baylor College of Medicine have now traced that resistance to a specific culprit — the LIG1 gene — and found a way to turn it against the cancer itself.
LIG1 encodes a DNA repair protein, and its loss forces cancer cells to lean heavily on alternative repair pathways just to survive. For years, low LIG1 was simply a marker of treatment failure. Dr. Meenakshi Anurag and her team asked a harder question: could that dependency be exploited? Working with collaborators at the Institute of Cancer Research in London, they screened olaparib, a PARP inhibitor, against 120 other DNA damage response drugs. The answer came back clearly — pairing olaparib with ceralasertib, an ATR inhibitor, was far more potent than either drug alone. In cell lines and animal models with both TP53 mutations and LIG1 loss, the combination significantly suppressed tumor growth.
The logic is mechanistic: by blocking both PARP and ATR, two nodes the cells depend on for repair, the researchers effectively closed every exit. The tumors could neither recover from chemotherapy damage nor from the drugs themselves. What makes this clinically meaningful is that LIG1 status can be measured in a patient's tumor before treatment begins — converting a negative finding into a precise signal for a specific therapeutic strategy.
Published in Molecular Cancer Therapeutics, the study points toward clinical trials where LIG1 status could guide patient selection. For a subset of patients who have exhausted conventional options, this disciplined, mechanism-first approach may represent a genuine way forward.
Triple-negative breast cancer is among the most punishing diagnoses in oncology. It lacks the hormone receptors that make other breast cancers treatable with targeted drugs, and it spreads fast. For patients whose tumors also carry mutations in the TP53 gene—a critical tumor suppressor—the outlook darkens further. Many of them develop resistance to platinum-based chemotherapy, the standard weapon against this disease. Researchers at Baylor College of Medicine have now traced that resistance to a specific genetic loss and, more importantly, found a way to exploit it.
The culprit is the LIG1 gene, which encodes a DNA repair protein. When cancer cells lose one copy of this gene, they become stubbornly resistant to platinum drugs. For years, this was simply a bad-news finding: a marker of treatment failure. But Dr. Meenakshi Anurag and her team asked a different question. If LIG1 loss creates this resistance, could it also create a vulnerability they could weaponize?
They started by testing PARP inhibitors—FDA-approved drugs that block enzymes involved in DNA repair. The results were modest. Then Anurag's team, working with collaborators at the Institute of Cancer Research in London, screened PARP inhibitors against 120 other DNA damage response inhibitors to find a partner drug. What emerged was striking: combining olaparib, a PARP inhibitor, with ceralasertib, an ATR inhibitor, proved far more potent than either drug alone. In cell lines and animal models carrying both TP53 mutations and LIG1 loss, the combination significantly reduced tumor growth.
The mechanism matters. LIG1 loss forces cancer cells to rely more heavily on alternative DNA repair pathways. By blocking both PARP and ATR—two critical nodes in those pathways—the researchers essentially trapped the cells. They could not repair the damage from chemotherapy or from the drugs themselves. It is a mechanistic approach, grounded in understanding exactly why these tumors resist treatment, rather than throwing drugs at the problem and hoping something sticks.
What makes this work clinically actionable is the biomarker. LIG1 status can be measured in a patient's tumor before treatment begins. If levels are low, that patient becomes a candidate for the olaparib-ceralasertib combination. This transforms a negative finding—chemotherapy resistance—into a positive one: a clear signal for a specific, rational treatment strategy. The researchers hope LIG1 status will guide patient selection in upcoming clinical trials, allowing them to enroll the patients most likely to benefit.
Triple-negative breast cancer with TP53 mutations remains a formidable opponent. But this work suggests a path forward for a subset of patients who have run out of options. The study, published in Molecular Cancer Therapeutics, represents the kind of disciplined, mechanistic thinking that has slowly begun to crack some of oncology's hardest problems. The next step is the clinic—and whether this laboratory promise translates into better outcomes for the women who need it most.
Notable Quotes
We started by identifying LIG1 loss as a marker of chemotherapy resistance, initially a negative finding. The question became whether we could leverage this discovery to identify a clinical-grade treatment strategy.— Dr. Meenakshi Anurag, Baylor College of Medicine
LIG1 loss looks promising as a predictive biomarker for ATR/PARP inhibitor combinations, following the success of PARP inhibition in BRCA-deficient tumors.— Dr. Matthew Ellis, State University of Campinas
Want the full story?
Read the original at Medical Xpress ↗
Health & Medicine